SCHEMBL16608976

SCHEMBL16608976

CC(C)(C)OC(=O)NC1CCN(c2c(Br)cncc2[N+](=O)[O-])CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 1/20 0.45
▸ SKP1 P63208 1/20 0.45
▸ SKP2 Q13309 1/20 0.45
▸ DRD2 P14416 3/20 0.40
▸ SUV39H2 Q9H5I1 4/20 0.39
▸ CTSK P43235 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ OPRK1 P41145 2/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ OPRD1 P41143 1/20 0.37
▸ OGFRL1 Q5TC84 1/20 0.37
▸ KCNA3 P22001 1/20 0.37
▸ JAK3 P52333 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ NPY5R Q15761 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ PIM1 P11309 1/20 0.35
▸ PIM3 Q86V86 1/20 0.35
▸ PIM2 Q9P1W9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16695012 0.85 CKS1B (0.47) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL30628505 0.84 EIF2AK4 (0.41) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL16608911 0.84 RET (0.41) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL16608964 0.84 RET (0.41) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL16608958 0.84 RET (0.41) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL16608907 0.84 RET (0.41) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL17965887 0.84 POLB (0.38) MAPTTDP1OPRK1USP7USP47
SCHEMBL16522584 0.83 CTSK (0.42) CKS1BSKP1SKP2SUV39H2CTSK
SCHEMBL17965894 0.82 CKS1B (0.49) CKS1BSKP1SKP2DRD2SUV39H2
SCHEMBL16608959 0.82 CKS1B (0.42) CKS1BSKP1SKP2DRD2SUV39H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3053916-B1 COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO (JP) 2019-01-30 — — EP disclosed
US-9643951-B2 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2017-05-09 — — US disclosed
US-9643951-B2 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2017-05-09 — — US disclosed
US-9643951-B2 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2017-05-09 — — US disclosed
US-20160311794-A1 COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-27 — — US disclosed
US-20160311794-A1 COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-27 — — US disclosed
US-20160311794-A1 COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-27 — — US disclosed
WO-2015046482-A1 COMPOUND HAVING AGONISTIC ACTIVITY TO SOMATOSTATIN RECEPTOR AND MEDICINAL USE THEREOF 小野薬品工業株式会社 2015-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311794-A1 COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF SSTR1, SSTR2, SSTR3 CKS1B 4574/4885SKP1 1214/4885SKP2 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback